Rituxan News
Most Popular Rituxan Story
MAbs are hottest segment of biotech industry
Looking for the hottest segment of the biotech industry? Then take a look at monoclonal antibodies (mAbs). A new Datamonitor report projects 14 percent annual growth in the market for the antibody... Read more...
Latest Headlines
- June 17, 2009
- April 29, 2008
- April 15, 2008
- March 19, 2008
- January 29, 2008
- January 15, 2008
- November 8, 2007
- October 29, 2007
- October 24, 2007
- October 12, 2007
- September 12, 2007
- January 24, 2007
- January 22, 2007
- January 9, 2007
- December 19, 2006
- December 19, 2006
- December 18, 2006
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
